Scholarlink

<p>This study was to evaluate the cost-effectiveness of toripalimab with bevacizumab compared to sorafenib for advanced hepatocellular carcinoma (HCC) from the Chinese healthcare system perspective. To assess the cost and health outcomes of first-line advanced HCC therapy, we used a partitioned survival model.The model clinical dates were base on the Phase III HEPATORCH trials.The costs considered in this analysis such as drug costs, subsequent therapy cost, and the management of adverse events cost.Quality-adjusted life years (QALY) were used to measure health outcomes and the main economic assessment parameter was the incremental cost-effectiveness ratio (ICER).The willing to pay (WTP) level was 41,876.05 USD per QALY.The robustness and reliability of the model were evaluated using sensitivity analysis. The total cost of toripalimab plus bevacizumab treatment were 45,516.45 USD, while the sorafenib incurred costs of 24,579.02 USD. In compared to sorafenib, the toripalimab plus bevacizumab group achieved an additional 1.35 QALYs and an additional cost of 120,937.43 USD. The ICER was 15,509.21 USD per QALY for the toripalimab plus bevacizumab.One-way sensitivity analysis showed that our results were not reversed when the input paramete fluctuated ± 25%.Toripalimab plus bevacizumab had a 99% chance of being cost-effective at the WTP level. The therapy of toripalimab and bevacizumab was found to be a cost-effective treatment option for patients with advanced HCC in China.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost-effectiveness analysis of toripalimab and bevacizumab versus sorafenib for advanced hepatocellular carcinoma in China

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月18日

查看全文
  • Zhiwei Zheng,
  • Tian Liu,
  • Yuling Zhang,
  • Huide Zhu,
  • Ling Fang

摘要

This study was to evaluate the cost-effectiveness of toripalimab with bevacizumab compared to sorafenib for advanced hepatocellular carcinoma (HCC) from the Chinese healthcare system perspective. To assess the cost and health outcomes of first-line advanced HCC therapy, we used a partitioned survival model.The model clinical dates were base on the Phase III HEPATORCH trials.The costs considered in this analysis such as drug costs, subsequent therapy cost, and the management of adverse events cost.Quality-adjusted life years (QALY) were used to measure health outcomes and the main economic assessment parameter was the incremental cost-effectiveness ratio (ICER).The willing to pay (WTP) level was 41,876.05 USD per QALY.The robustness and reliability of the model were evaluated using sensitivity analysis. The total cost of toripalimab plus bevacizumab treatment were 45,516.45 USD, while the sorafenib incurred costs of 24,579.02 USD. In compared to sorafenib, the toripalimab plus bevacizumab group achieved an additional 1.35 QALYs and an additional cost of 120,937.43 USD. The ICER was 15,509.21 USD per QALY for the toripalimab plus bevacizumab.One-way sensitivity analysis showed that our results were not reversed when the input paramete fluctuated ± 25%.Toripalimab plus bevacizumab had a 99% chance of being cost-effective at the WTP level. The therapy of toripalimab and bevacizumab was found to be a cost-effective treatment option for patients with advanced HCC in China.